Holen Sie sich die Stockscreener-App
24.28
4.07%
-1.03
Handel nachbörslich:
24.70
0.42
+1.73%
Monte Rosa Therapeutics Inc Aktie (GLUE) Neueste Nachrichten
Insider Sell: Markus Warmuth Sells Shares of Monte Rosa Therapeu - GuruFocus
Monte Rosa Therapeutics (NASDAQ:GLUE) CEO Markus Warmuth Sells 5,466 Shares - MarketBeat
Finance Watch: Aktis Tests 2026 IPO Waters With Year’s First Offering, Raising $318m - Citeline News & Insights
Monte Rosa Therapeutics Prices Underwritten Public Offering Of $300 Mln Of Shares - Nasdaq
Why Monte Rosa Therapeutics Inc. stock is considered a top pickWeekly Investment Recap & Risk Managed Investment Strategies - ulpravda.ru
Monte Rosa Therapeutics prices $300 million public offering - Investing.com
Biotech Monte Rosa is selling $300M in new shares to investors - Stock Titan
Monte Rosa Therapeutics announces pricing of $300 million underwritten public offering at $24.00 per share - MarketScreener
Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering - Yahoo Finance
How institutional buying supports Monte Rosa Therapeutics Inc. stockJuly 2025 Highlights & Daily Market Momentum Tracking - ulpravda.ru
Can Monte Rosa Therapeutics Inc. stock beat analyst upgradesJuly 2025 Highlights & AI Forecasted Stock Moves - ulpravda.ru
GLUE Stock: Guggenheim Maintains Buy Rating, Raises Price Target - GuruFocus
Will Monte Rosa Therapeutics Inc. stock attract more institutional investorsWeekly Investment Summary & Free AI Powered Buy and Sell Recommendations - ulpravda.ru
Is Monte Rosa Therapeutics Inc. stock a safe investment in uncertain marketsJuly 2025 Snapshot & Accurate Buy Signal Notifications - ulpravda.ru
GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug - Finviz
Why Monte Rosa Therapeutics Inc. stock is a must watch in 2025Weekly Profit Summary & Community Trade Idea Sharing - ulpravda.ru
Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says - MarketBeat
GLUE Stock Receives Analyst Rating Update with Raised Price Targ - GuruFocus
Monte Rosa Therapeutics (GLUE) is on the Move, Here's Why the Trend Could be Sustainable - sharewise.com
Monte Rosa Therapeutics (NASDAQ:GLUE) Given New $34.00 Price Target at Guggenheim - MarketBeat
Monte Rosa Therapeutics: Competitive MRT-8102 Results Offer Additional Platform Validation - Seeking Alpha
Monte Rosa Therapeutics Reaches Analyst Target Price - Nasdaq
Monte Rosa Therapeutics dips after $200 mln equity offering launched - TradingView — Track All Markets
Zacks Research Upgrades Monte Rosa Therapeutics (NASDAQ:GLUE) to Strong-Buy - MarketBeat
Monte Rosa Therapeutics launches $200 million public offering By Investing.com - Investing.com Nigeria
Monte Rosa Therapeutics launches $200M public equity offering - MSN
Monte Rosa Therapeutics (GLUE) upgraded to strong buy: Here's why - MSN
The Great Thaw: Biotech Fundraising Surges as Monte Rosa and Genelux Tap Reopening Markets - FinancialContent
Monte Rosa Therapeutics Ends Current ATM Equity Program - TipRanks
Monte Rosa Therapeutics launches $200 million public offering - Investing.com
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - The Manila Times
Biotech working on new medicines moves to raise $200M - Stock Titan
Monte Rosa Therapeutics (GLUE) Soars on Promising Inflammation Drug Data - RagingBull
Monte Rosa Therapeutics (GLUE) Upgraded to Strong Buy: Here's Why - sharewise.com
Cardio works out for Monte Rosa in NEK7 phase I - BioWorld MedTech
Monte Rosa Therapeutics price target raised to $37 from $26 at Wedbush - TipRanks
Monte Rosa Therapeutics (NASDAQ:GLUE) Hits New 12-Month HighShould You Buy? - MarketBeat
GLUE: MRT-8102 achieved robust hsCRP and fibrinogen reductions with favorable safety in phase I - TradingView — Track All Markets
Why Is Monte Rosa Therapeutics Stock Skyrocketing Wednesday?Monte Rosa Therapeutics (NASDAQ:GLUE) - Benzinga
Monte Rosa Therapeutics: Early MRT-8102 hsCRP Data Underscore Differentiated NLRP3 Opportunity and Attractive Risk-Reward Supporting Buy Rating - TipRanks
Monte Rosa Therapeutics, Ventyx Biosciences, United Microelectronics And Other Big Stocks Moving Higher On Wednesday - Benzinga
Monte Rosa Therapeutics stock hits 52-week high at $21.89 - Investing.com
Monte Rosa Therapeutics Shares Phase 1 MRT-8102 Data Showing 85% hsCRP Drop, No Safety Flags - MarketBeat
GLUE Hits New High On Positive Phase 1 Data For MRT-8102 In Cardiovascular Risk Participants - RTTNews
Here’s Why Monte Rosa Therapeutics Stock (GLUE) Rocketed Today - TipRanks
Monte Rosa’s MRT-8102 shows promising results in reducing inflammation By Investing.com - Investing.com Nigeria
Why Did GLUE Stock Surge Over 50% In Premarket Today? - Stocktwits
Did Monte Rosa’s Interim MRT-8102 Data Reveal a Turning Point for Its Molecular Glue Platform (GLUE)? - simplywall.st
Monte Rosa reports positive Phase 1 data for MRT-8102 - TipRanks
Monte Rosa’s MRT-8102 shows promising results in reducing inflammation - Investing.com India
Monte Rosa Therapeutics Reports Positive Interim Data from Phase 1 Study of MRT-8102 in Reducing Inflammation in Cardiovascular Disease Risk Patients - Quiver Quantitative
Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 - TradingView — Track All Markets
Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects - The Manila Times
Monte Rosa Therapeutics Announces Positive Interim Phase 1 - GlobeNewswire
Monte Rosa (GLUE) Stock Pre-Market (+8.7%): Positive Phase 1 Data for MRT-8102 - Trefis
Stocks to Watch: Mobileye Global, AAR, Monte Rosa Therapeutics - 富途牛牛
Monte Rosa to present interim results for NEK7-directed MGD By Investing.com - Investing.com South Africa
Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results - The Manila Times
Early trial results for a new drug targeting heart disease risk go public - Stock Titan
How Monte Rosa Therapeutics Inc. stock reacts to inflationary pressures2026 world cup usa national team semifinals key players counter attacking odds analysis breakdown - ulpravda.ru
Monte Rosa Therapeutics (NASDAQ:GLUE) Trading Down 8.2%Here's Why - MarketBeat
Monte Rosa reports positive phase 1/2 study results - MSN
Monte Rosa stock surges after positive data shows 85% CRP reduction - Investing.com
Monte Rosa Therapeutics (NASDAQ:GLUE) Shares Down 6.4%Here's Why - MarketBeat
Monte Rosa Therapeutics (GLUE) price target increased by 22.54% to 21.78 - MSN
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):